Immunovant, Inc.

Informe acción NasdaqGS:IMVT

Capitalización de mercado: US$3.8b

Salud financiera de hoja de balance de Immunovant

Salud financiera controles de criterios 6/6

Immunovant tiene un patrimonio de los accionistas total de $679.3M y una deuda total de $0.0, lo que sitúa su ratio deuda-patrimonio en 0%. Sus activos y pasivos totales son $711.4M y $32.1M respectivamente.

Información clave

0%

Ratio deuda-patrimonio

US$0

Deuda

Ratio de cobertura de interesesn/a
EfectivoUS$635.37m
PatrimonioUS$617.76m
Total pasivoUS$48.61m
Activos totalesUS$666.37m

Actualizaciones recientes sobre salud financiera

Recent updates

We're Hopeful That Immunovant (NASDAQ:IMVT) Will Use Its Cash Wisely

Apr 19
We're Hopeful That Immunovant (NASDAQ:IMVT) Will Use Its Cash Wisely

Immunovant: Strategic Edge In The Autoimmune Sector (Rating Upgrade)

Apr 04

Immunovant: An Intriguing And Developing Story

Jan 25

Immunovant, Inc. (NASDAQ:IMVT) Shares Could Be 33% Below Their Intrinsic Value Estimate

Jan 12
Immunovant, Inc. (NASDAQ:IMVT) Shares Could Be 33% Below Their Intrinsic Value Estimate

We're Hopeful That Immunovant (NASDAQ:IMVT) Will Use Its Cash Wisely

Sep 28
We're Hopeful That Immunovant (NASDAQ:IMVT) Will Use Its Cash Wisely

Here's Why We're Not Too Worried About Immunovant's (NASDAQ:IMVT) Cash Burn Situation

Jun 14
Here's Why We're Not Too Worried About Immunovant's (NASDAQ:IMVT) Cash Burn Situation

Immunovant (NASDAQ:IMVT) Is In A Good Position To Deliver On Growth Plans

Mar 08
Immunovant (NASDAQ:IMVT) Is In A Good Position To Deliver On Growth Plans

We're Not Very Worried About Immunovant's (NASDAQ:IMVT) Cash Burn Rate

Nov 06
We're Not Very Worried About Immunovant's (NASDAQ:IMVT) Cash Burn Rate

Immunovant: Capitalizing On Fast Growing FcRn Space With Novel Asset

Oct 17

Immunovant stock down on raising $75M though equity capital

Oct 04

We're Not Very Worried About Immunovant's (NASDAQ:IMVT) Cash Burn Rate

Aug 06
We're Not Very Worried About Immunovant's (NASDAQ:IMVT) Cash Burn Rate

Here's Why We're Not Too Worried About Immunovant's (NASDAQ:IMVT) Cash Burn Situation

Apr 06
Here's Why We're Not Too Worried About Immunovant's (NASDAQ:IMVT) Cash Burn Situation

We're Hopeful That Immunovant (NASDAQ:IMVT) Will Use Its Cash Wisely

Jun 20
We're Hopeful That Immunovant (NASDAQ:IMVT) Will Use Its Cash Wisely

Immunovant EPS beats by $0.04

Jun 01

argenx rise even as Immunovant pauses the trial for anti-FcRn therapy

Feb 03

Immunovant slips 7% on voluntary hold of IMVT-1401 dosing

Feb 02

Immunovant: IMVT-1401's Indication Expansion, $444M In Cash And New Management

Jan 14

Have Insiders Been Buying Immunovant, Inc. (NASDAQ:IMVT) Shares?

Dec 30
Have Insiders Been Buying Immunovant, Inc. (NASDAQ:IMVT) Shares?

Immunovant (IMVT) Investor Presentation - Slideshow

Nov 16

Análisis de la situación financiera

Pasivos a corto plazo: Los activos a corto plazo ($710.8M) de IMVT superan a sus pasivos a corto plazo ($32.1M).

Pasivo a largo plazo: IMVT no tiene pasivos a largo plazo.


Historial y análisis de deuda-patrimonio

Nivel de deuda: IMVT está libre de deudas.

Reducción de la deuda: IMVT no tenía deudas hace 5 años.


Hoja de balance


Análisis de cash runway

En el caso de las empresas que de media han sido deficitarias en el pasado, evaluamos si tienen al menos 1 año de cash runway.

Cash runway estable: IMVT tiene suficiente cash runway para más de un año basándose en su flujo de caja libre actual.

Pronóstico de cash runway: IMVT dispone de suficiente cash runway para 2.7 años si el flujo de caja libre sigue reduciéndose a tasas históricas de 27.8% cada año.


Descubre empresas con salud financiera